KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) EBIAT (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of EBIAT readings, the most recent being $369.0 million for Q1 2026.

  • On a quarterly basis, EBIAT rose 72.43% to $369.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.6 billion, a 214.07% increase, with the full-year FY2025 number at $1.4 billion, up 171.98% from a year prior.
  • EBIAT hit $369.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $480.0 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $480.0 million in Q4 2025 to a low of -$1.3 billion in Q4 2022.
  • Median EBIAT over the past 5 years was -$253.0 million (2023), compared with a mean of -$195.5 million.
  • Biggest five-year swings in EBIAT: crashed 1336.36% in 2022 and later skyrocketed 274.55% in 2025.
  • Teva Pharmaceutical Industries' EBIAT stood at -$1.3 billion in 2022, then skyrocketed by 134.58% to $461.0 million in 2023, then plummeted by 159.65% to -$275.0 million in 2024, then skyrocketed by 274.55% to $480.0 million in 2025, then dropped by 23.12% to $369.0 million in 2026.
  • The last three reported values for EBIAT were $369.0 million (Q1 2026), $480.0 million (Q4 2025), and $433.0 million (Q3 2025) per Business Quant data.